[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337068-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337068-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","antibodydrug-conjugates-a-start-of-a-new-era-in-gynecological-cancers","Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers","","Antibody–drug conjugates (ADCs) are targeted therapeutics that combine monoclonal antibody specificity with the cytotoxic action of chemotherapy agents. While ADCs have existed for over a decade, they remain relatively new in gynecological cancers, where more than 80% of active trials assess safety and efficacy and about 40% are early-phase studies. Approximately twenty ADCs are being investigated alone or with chemotherapy or immune checkpoint inhibitors. FDA approvals include mirvetuximabsoravtansine, tisotumab vedotin, and trastuzumab deruxtecan. Toxicity profiles are generally acceptable, with ocular toxicity often manageable using prophylactic steroids and dose adjustments. This review summarizes ADC fundamentals and the latest promising evidence, emphasizing a Canadian perspective.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/antibodydrug-conjugates-a-start-of-a-new-era-in-gynecological-cancers/337068/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/antibodydrug-conjugates-a-start-of-a-new-era-in-gynecological-cancers/337068.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are antibody–drug conjugates (ADCs) and how do they work?","Question",{"text":63,"@type":64},"ADCs are therapeutic agents designed to target specific antigens on tumor cells. They combine monoclonal antibody specificity with cytotoxic drug activity to deliver chemotherapy effects more directly to cancer cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How advanced is ADC research in gynecological cancers and what does the trial landscape look like?",{"text":68,"@type":64},"More than 80% of ongoing trials in gynecological cancers evaluate ADC safety and efficacy, and around 40% are early-phase trials. Roughly twenty ADCs are under investigation, either alone or in combination with chemotherapy or immune checkpoint inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"Which ADCs have been approved by the FDA for gynecological cancers mentioned in the review?",{"text":72,"@type":64},"The review notes FDA approval of mirvetuximabsoravtansine for platinum-resistant ovarian cancer with high folate-α receptor expression. It also states that tisotumab vedotin and trastuzumab deruxtecan are approved for patients with pre-treated cervical and uterine cancers, with further investigation ongoing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337068,1790244520,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Review  \nAntibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers  \nSamir Fasih 1, Stephen Welch 1 and Ana Elisa Lohmann 1,2, *  \nCitation: Fasih, S.; Welch, S.; Lohmann, A.E. Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers. Curr. Oncol. 2024, 31, 7088–7106. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/curroncol31110522](10.3390/curroncol31110522)  \nReceived: 21 August 2024  \nRevised: 30 October 2024  \nAccepted: 8 November 2024  \nPublished: 13 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Oncology, Division of Medical Oncology, University of Western Ontario, London, ON N6A 5W9, Canada; [samir.fasih@lhsc.on.ca](samir.fasih@lhsc.on.ca) (S.F.); [stephen.welch@lhsc.on.ca](stephen.welch@lhsc.on.ca) (S.W.)  \n2 Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON N6A 5W9, Canada  \n* Correspondence: [ana.lohmann@lhsc.on.ca](ana.lohmann@lhsc.on.ca); Tel.: +1-519-685-8640 (ext. 53292); Fax: +1-519-685-8808  \nAbstract: Antibody–drug conjugates (ADCs) are a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies with the cytotoxicity of chemotherapy agents. ADCs have been available for over a decade, but in gynecological cancers, these agents are relatively new with great promise ahead. More than 80% of ongoing trials in gynecological cancers are evaluating ADCs’ safety and efficacy, of which 40% are early-phase trials. Around twenty ADCs are currently under investigation, either alone or in combination with chemotherapies or immune checkpoint inhibitors. Among them, mirvetuximabsoravtansine has been recently approved by the Food and Drug Administration (FDA) in platinumresistant ovarian cancer with high folate-α receptor expression, as a single agent or in combination. Tisotumab vedotin and trastuzumab deruxtecan are also now approved by the FDA in patients with pre-treated cervical and uterine cancers and further investigation is ongoing. Overall, the toxicity profiles of ADCs are acceptable. Ocular toxicity is one of the specific side effects of some ADCs, but most of the cases are manageable with the use of prophylactic steroids and dose adjustments. This review aims to provide an overview of the fundamental and operational features of ADCs and examine the latest and most promising data, with a particular focus on the Canadian viewpoint.  \nKeywords: antibody drug conjugates; gynecological cancers; ovarian cancer; cervical cancer  \n1. Introduction  \nGynecological cancers are a group of neoplasms of female reproductive organs and genitals, including carcinomas of the vagina, vulva, cervix, uterus, ovaries, and fallopian tubes. Based on the statistics latest data available until the year 2022, cancer is the most common cause of death in Canada [1]. The most common gynecological cancer is uterine cancer (7.4%), followed by ovarian (2.7%) and cervical (1.4%), respectively [2]. The treatment of gynecological tumors depends on the cancer type and disease stage. Patients with distant metastasis or recurrences have a poor outcome with uterine and cervical cancer, having a 5-year survival rate of around 18%[3]. In ovarian cancer, the majority of patients present with advanced disease at initial diagnosis [4]. Despite excellent responses to surgery and chemotherapy, more than 80%[5] will relapse and eventually become platinum resistant. Recently, many immunotherapeutic treatments, including immune checkpoint inhibitors and monoclonal antibodies, have been used for treatment in gynecological malignancies, especially for uterine and cer","cbCaiksrwngmUKdo","https://ap.wps.com/l/cbCaiksrwngmUKdo","pdf",746667,"English","# Introduction\n# ADCs: Mechanism of Action\n## Structure","[{\"question\":\"What are antibody–drug conjugates (ADCs) and how do they work?\",\"answer\":\"ADCs are therapeutic agents designed to target specific antigens on tumor cells. They combine monoclonal antibody specificity with cytotoxic drug activity to deliver chemotherapy effects more directly to cancer cells.\"},{\"question\":\"How advanced is ADC research in gynecological cancers and what does the trial landscape look like?\",\"answer\":\"More than 80% of ongoing trials in gynecological cancers evaluate ADC safety and efficacy, and around 40% are early-phase trials. Roughly twenty ADCs are under investigation, either alone or in combination with chemotherapy or immune checkpoint inhibitors.\"},{\"question\":\"Which ADCs have been approved by the FDA for gynecological cancers mentioned in the review?\",\"answer\":\"The review notes FDA approval of mirvetuximabsoravtansine for platinum-resistant ovarian cancer with high folate-α receptor expression. It also states that tisotumab vedotin and trastuzumab deruxtecan are approved for patients with pre-treated cervical and uterine cancers, with further investigation ongoing.\"}]","Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers | PDF",1790017613,48]